Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00496873
Status:
COMPLETED
Last Update Posted:
2023-03-29
First Post:
2007-07-03
Brief Title:
Evaluation of the Safety and Efficacy of Nipent Cytoxan and Rituxan
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Lymphoma |
Keywords:
| Name | View |
|---|---|
| Pentostatin | View |
| Non-Hodgkins Lymphoma | View |
| NHL | View |
| Lymphoma | View |
| B-cell chronic lymphocytic leukemia | View |
| SLL | View |
| Small Lymphocytic Lymphoma | View |
| Lymphoplasmacytic lymphomaimmunocytoma | View |
| Follicular lymphoma | View |
| Extranodal marginal zone B-cell lymphoma of MALT type | View |
| Nodal marginal zone B-cell lymphoma | View |
| Chronic Lymphocytic Leukemia | View |
| CLL | View |
| Bulky Lymphoma | View |
| Nipent | View |
| Cytoxan | View |
| Rituxan | View |
| Cyclophosphamide | View |
| Rituximab | View |